chevron_leftBack
As of 24 April 2025, Hofseth BioCare ASA has a market cap of $76.65M USD, ranking #22291 globally and #149 in Norway. It ranks #2230 in the Healthcare sector, and #693 in the Biotechnology industry.
Key Stats
Market Cap
$76.65MUSD
797.5M NOK
Enterprise Value
$89.45MUSD
942.11M NOK
Revenue (TTM)
$25.52MUSD
265.54M NOK
EBITDA (TTM)
-$6.2MUSD
-65.3M NOK
Net Income (TTM)
-$11.86MUSD
-123.41M NOK
EBITDA Margin
-25%
Profit Margin
-46%
Company Profile
Country (HQ)
Sector
Healthcare
Industry
Biotechnology
CEO
Jon Odegard
open_in_new
Employees
71
Founded
2000
Website
hofsethbiocare.com
open_in_new
warningChart data may be delayed
| 1d | 1w | 1m | 3m | 6m | 1y |
|---|---|---|---|---|---|
| -7.2% | -1.5% | -16% | -32% | 31% | -11% |
Markets
| Exchange | Ticker | Price |
|---|---|---|
|
HBC
ISIN: NO0010598683
Shares Out.:
Shares Outstanding:
395.081M1
Shares Float:
190.84M2
|
1.80 NOK | |
|
0Q6H
Hofseth BioCare ASA
ISIN: NO0010598683
|
2.09 NOK | |
|
HBCO
Hofseth BioCare ASA
ISIN: NO0010598683
TV:
TradingView:
SA:
Stock Analysis:
YF:
Yahoo Finance:
GF:
Google Finance:
BA:
Barron's:
MS:
Morningstar:
|
2.02 NOK | |
|
HOFBF
Hofseth BioCare ASA
ISIN: NO0010598683
TV:
TradingView:
SA:
Stock Analysis:
YF:
Yahoo Finance:
GF:
Google Finance:
BA:
Barron's:
MS:
Morningstar:
|
0.1550 USD |
1Market cap is calculated using shares outstanding.
2Float shares are publicly tradable shares, excluding insider-held stock.
About Hofseth BioCare ASA
Hofseth BioCare ASA operates as a consumer and pet health ingredient supplier and incubator in Norway, the United Kingdom, France, Belgium, Europe, Japan, Asia, and the United States. The company’s products include OmeGo, a salmon oil, which offers the full spectrum of fatty acids and omegas found naturally in fresh whole salmon; ProGo, a bioactive peptide for VMS, metabolism, and active nutrition needs; CalGo, an absorbable complex mineral for bone and joint health; CollaGo; and PetGo, a non-soluble protein. The company was incorporated in 2000 and is headquartered in Ålesund, Norway.
